Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference


SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16. During the conference, Nancy Chang, Ph.D., chief executive officer of Ansun, will deliver a corporate update to potential investors registered for the meeting. The corporate update will cover recent and upcoming company milestones, as well as detail clinical progress of the company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases, including influenza and parainfluenza, by preventing viral entry into respiratory epithelial cells. Ansun is also assessing DAS181 in patients with severe COVID-19 in Phase 2 studies.

Read the original post:
Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Related Posts